The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children
- PMID: 22946905
- PMCID: PMC3513608
- DOI: 10.1111/j.1475-6773.2012.01461.x
The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children
Abstract
Objective: To describe the relationship between mental health diagnosis and treatment with antipsychotics among U.S. Medicaid-enrolled children over time.
Data sources/study setting: Medicaid Analytic Extract (MAX) files for 50 states and the District of Columbia from 2002 to 2007.
Study design: Repeated cross-sectional design. Using logistic regression, outcomes of mental health diagnosis and filled prescriptions for antipsychotics were standardized across demographic and service use characteristics and reported as probabilities across age groups over time.
Data collection: Center for Medicaid Services data extracted by means of age, ICD-9 codes, service use intensity, and National Drug Classification codes.
Principal findings: Antipsychotic use increased by 62 percent, reaching 354,000 youth by 2007 (2.4 percent). Although youth with bipolar disorder, schizophrenia, and autism proportionally were more likely to receive antipsychotics, youth with attention deficit hyperactivity disorder (ADHD) and those with three or more mental health diagnoses were the largest consumers of antipsychotics over time; by 2007, youth with ADHD accounted for 50 percent of total antipsychotic use; 1 in 7 antipsychotic users were youth with ADHD as their only diagnosis.
Conclusions: In the context of safety concerns, disproportionate antipsychotic use among youth with nonapproved indications illustrates the need for more generalized efficacy data in pediatric populations.
© Health Research and Educational Trust.
Figures




Similar articles
-
Trends in Antipsychotic Prescribing in Medicaid-Eligible Youth.J Am Acad Child Adolesc Psychiatry. 2017 Jan;56(1):59-66. doi: 10.1016/j.jaac.2016.10.005. Epub 2016 Oct 24. J Am Acad Child Adolesc Psychiatry. 2017. PMID: 27993230
-
Treatment of Young People With Antipsychotic Medications in the United States.JAMA Psychiatry. 2015 Sep;72(9):867-74. doi: 10.1001/jamapsychiatry.2015.0500. JAMA Psychiatry. 2015. PMID: 26132724
-
Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011.Eur Child Adolesc Psychiatry. 2017 Apr;26(4):413-420. doi: 10.1007/s00787-016-0905-7. Epub 2016 Sep 13. Eur Child Adolesc Psychiatry. 2017. PMID: 27623818
-
A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents.Can J Psychiatry. 2012 Dec;57(12):717-21. doi: 10.1177/070674371205701202. Can J Psychiatry. 2012. PMID: 23228229 Review.
-
Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.Int J Neuropsychopharmacol. 2014 Jul;17(7):1095-105. doi: 10.1017/S1461145712001320. Epub 2013 May 14. Int J Neuropsychopharmacol. 2014. PMID: 23673334 Free PMC article. Review.
Cited by
-
Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.Eur Child Adolesc Psychiatry. 2021 Jul;30(7):1047-1058. doi: 10.1007/s00787-020-01589-2. Epub 2020 Jul 3. Eur Child Adolesc Psychiatry. 2021. PMID: 32621088 Review.
-
Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.Paediatr Drugs. 2016 Aug;18(4):319-29. doi: 10.1007/s40272-016-0183-3. Paediatr Drugs. 2016. PMID: 27278054 Clinical Trial.
-
Psychotropic drug use among preschool children in the Medicaid program from 36 states.Am J Public Health. 2015 Mar;105(3):524-9. doi: 10.2105/AJPH.2014.302258. Epub 2015 Jan 20. Am J Public Health. 2015. PMID: 25602884 Free PMC article.
-
Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.Pharmacotherapy. 2014 Aug;34(8):836-44. doi: 10.1002/phar.1453. Epub 2014 Jul 3. Pharmacotherapy. 2014. PMID: 24990538 Free PMC article.
-
Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.Health Serv Res. 2020 Aug;55(4):596-603. doi: 10.1111/1475-6773.13297. Epub 2020 Jun 21. Health Serv Res. 2020. PMID: 32567089 Free PMC article.
References
-
- Andrade S, Lo J, Roblin D, Fouayzi H, Connor D, Penfuld R, Chandra M, Reed G, Gurwitz J. “Antipsychotic Medication Use among Children and Risk of Diabetes Mellitus”. Pediatrics. 2011;128(6):1135–41. - PubMed
-
- Biederman J, Mick E, Faraone SV, Wozniak J, Spencer T, Pandina G. “Risperidone for the Treatment of Affective Symptoms in Children with Disruptive Behavior Disorder: A Post Hoc Analysis of Data from a 6-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm Study”. Clinical Therapeutics. 2006;28(5):794–800. - PubMed
-
- Coe H, Hong I. “Safety of Low Doses of Quetiapine When Used for Insomnia”. Pharmacotherapy. 2012;46(5):718–22. - PubMed
-
- Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA. “Trends in Prescribing of Antipsychotic Medications for US Children”. Ambulatory Pediatrics. 2006;6(2):79–83. - PubMed
-
- Correll CU. “Assessing and Maximizing the Safety and Tolerability of Antipsychotics Used in the Treatment of Children and Adolescents”. Journal of Clinical Psychiatry. 2008a;69(suppl 4):26–36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical